Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a sustained control of symptoms for Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from the nine-month extension study (NCT03877510) indicate dose adjustments and side effects were…

Exposure to low oxygen may help to ease the symptoms of Parkinson’s disease — but a lot more research is needed to conclusively determine the safety and effectiveness of this strategy for use among people with the neurodegenerative disorder, according to a new report. “From a clinical perspective, hypoxia…

Managing medications is a common responsibility for those with Parkinson’s disease and many other conditions. According to Georgetown University’s Health Policy Institute, more than 131 million people — 66% of U.S. adults — use prescription drugs. With Parkinson’s disease, managing medications is a balancing act required for us to…

Top-line results are expected to be released by the end of this year for Pharma Two B’s multinational trial investigating the safety and efficacy of P2B001 for treating early stage Parkinson’s disease. Pharma Two B announced that its researchers have finished treating patients in the Phase 3 trial, which…

The impact of deep brain stimulation (DBS) in improving motor function in people with Parkinson’s disease may be related to a patient’s response to levodopa therapy, and to the type of DBS administered, according to a small study. Patients who responded to levodopa demonstrated better…

A voice therapy program called SPEAK OUT!, developed by the Parkinson Voice Project, can help Parkinson’s disease patients regain their ability to communicate, according to a new study. Parkinson’s patients, especially those who received the training in early stages of the disease, saw improvements in speech intensity, pitch…

Improved understanding of Parkinson’s disease psychosis (PDP) and a unified approach for its clinical evaluation are key for developing new therapeutics, a review study suggests. The research, “Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis,” was published in the journal Current Psychiatry Reports. PDP has been…

Inbrija reduces Parkinson’s symptoms when standard treatments wear off, and decreases the length of these off periods, a Phase 3 clinical trial shows. The therapy’s developer, Acorda Therapeutics, will present the results at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. Parkinson’s News Today will be covering…

Acorda Therapeutics has asked the European Medicines Agency to approve Inbrija (CVT-301) to reduce the periods when the standard Parkinson’s treatment carbidopa/levodopa is not working. Inbrija is a self-administered, inhaled levodopa therapy. Acorda developed it to reduce the time when standard levodopa treatment wears off — periods known as off times.